fluorouracil has been researched along with Injuries, Radiation in 175 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Radiation enteritis is the main acute side-effect during pelvic irradiation." | 5.34 | Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. ( Bendahl, PO; Gunnlaugsson, A; Johnsson, A; Kjellén, E; Nilsson, P; Willner, J, 2007) |
| "This article describes a woman with metastatic upper gastrointestinal cancer who developed thoracic myelopathy unexpectedly after standard dosage and fractionation radiotherapy." | 5.33 | Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine. ( Barstis, JL; Black, AC, 2005) |
| "In this phase I study, we sought to determine the feasibility and tolerability of neoadjuvant short course radiotherapy (SC-CRT) delivered with photon RT with concurrent capecitabine for resectable pancreatic adenocarcinoma." | 5.19 | Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. ( Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY, 2014) |
| "A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811." | 5.17 | RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013) |
| "Radiation Therapy Oncology Group (RTOG) 92-08 began as a single arm, Phase II trial for patients with anal cancer consisting of radiation (RT) + 5-flourouracil + mitomycin-C with a mandatory 2-week break and was amended after completion to evaluate the same treatment regimen without a treatment break." | 5.13 | Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. ( Garcia, M; John, M; Konski, A; Krieg, R; Myerson, R; Pinover, W; Willett, C, 2008) |
| " Two patients with nasopharyngeal carcinoma complicated by collagen diseases (dermatomyositis in one, and Sjögren's syndrome with mixed connective tissue disease in the other) were given radiotherapy combined with chemotherapy consisting of cis-platinum and 5-fluorouracil." | 4.79 | Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature. ( Asakura, K; Hareyama, M; Hattori, A; Horikoshi, T; Hyodo, K; Imai, K; Koshiba, H; Morita, K; Nagakura, H; Oouchi, A; Sakata, K; Shido, M; Tamakawa, M; Tanaka, S, 1996) |
| "During a regular MR control, the patient developed anaphylactic reaction to Gadolinium, and after that a rectosigmoid ischemia with total necrosis of the posterior rectal wall was diagnosed and surgically treated with Hartmann procedure." | 3.91 | Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication. ( Calvisi, G; Carlei, F; Di Sibio, A; Di Staso, M; Giuliani, A; Lombardi, L; Marchese, M; Romano, L; Romanzi, F; Schietroma, M, 2019) |
| "From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma." | 3.79 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013) |
| "A 61-year-old man, with a tuberous sclerosis, experienced severe acute reactions during a concomitant chemoradiotherapy regimen after 22Gy and one cycle of 5-fluorouracil-cisplatinum." | 3.79 | [Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case]. ( Baruch-Hennequin, V; Duchemain, B; Duchemann, B; Hennequin, C; Quero, L; Rivera, S; Wong, S, 2013) |
| "A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer." | 3.74 | Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007) |
| "Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2." | 3.66 | Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study. ( Cassidy, M; Friedman, M; Levine, M; Phillips, T; Resser, KJ; Spivack, S, 1979) |
| "Radiation proctitis was identified by imaging in 9 (15." | 2.94 | Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. ( Cheng, YK; Gao, X; Huang, XY; Lan, P; Ma, TH; Qin, QY; Wang, L, 2020) |
| "A challenge in borderline resectable pancreatic cancer (BRPC) management is the high rate of positive posterior margins (PM)." | 2.82 | A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). ( Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C, 2016) |
| "The rates of anastomotic leakage and stenosis were calculated for each treatment arm." | 2.82 | Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. ( Deng, Y; Ma, T; Qin, Q; Wang, H; Wang, J; Wang, L; Zheng, J; Zhou, Z, 2016) |
| "From 1990-2006, 100 patients with nasopharyngeal cancer were treated with alternating chemoradiation at the Aichi Cancer Center." | 2.78 | Alternating chemoradiotherapy in patients with nasopharyngeal cancer: prognostic factors and proposal for individualization of therapy. ( Fuwa, N; Goto, Y; Kodaira, T; Mizoguchi, N; Nakahara, R; Nomura, M; Tachibana, H; Tomita, N, 2013) |
| "Fifty-eight anal cancer patients were treated with concurrent chemotherapy and IMRT." | 2.78 | Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy. ( Beriwal, S; DeFoe, SG; Heron, DE; Kabolizadeh, P, 2013) |
| "Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients." | 2.77 | Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012) |
| " Toxicity was monitored according to Common Terminology Criteria for Adverse Events." | 2.77 | Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. ( Becker, H; Beissbarth, T; Brockmöller, J; Christiansen, H; Conradi, LC; Gaedcke, J; Ghadimi, M; Hennies, S; Herrmann, MK; Hess, CF; Jo, P; Mergler, CP; Rave-Fränk, M; Schirmer, MA; Wolff, HA, 2012) |
| "Radiation injuries were reported in 37." | 2.75 | [Extended preoperative course of radiotherapy as component of combined and complex treatment of locally-advanced ampular rectal cancer]. ( Lukina, EIu; Nadvikova, EA; Semikopov, KV; Vazhenin, AV, 2010) |
| "Recommended dosage for future trials is capecitabine 625 mg/m bid, irinotecan 35 mg/m, and celecoxib 400 mg orally bid in combination with pelvic radiation." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1)." | 2.73 | Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. ( Brunner, TB; Grabenbauer, GG; Melzner, W; Rupp, A; Sauer, R, 2008) |
| "Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid." | 2.71 | Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. ( Ironside, JA; MacDougall, RH; Mais, KL; Slevin, NJ; Sykes, AJ, 2004) |
| "Neutropenia was the only grade-4 toxicity that occurred in 2 patients." | 2.71 | Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity. ( Ernst-Stecken, A; Grabenbauer, G; Iro, H; Plasswilm, L; Sauer, R, 2004) |
| "Treatment with sodium selenite is well tolerated and easy to deliver." | 2.71 | Selenium in the treatment of radiation-associated secondary lymphedema. ( Bruns, F; Büntzel, J; DeVries, AF; Glatzel, M; Kisters, K; Micke, O; Mücke, R; Schäfer, U; Schönekaes, K, 2003) |
| "Distant metastases remain the main cause of treatment failure in NPC." | 2.70 | Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| " 5-FU chemotherapy was administered as 120-hours continuous infusion in the first and fifth radiation week via a central venous catheter in a daily dosage of 1,000 mg/m2." | 2.69 | Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. ( Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S, 2000) |
| "Fibrosis was estimated by palpation in 404 patients by four physicians." | 2.67 | Dose and volume effects on fibrosis after breast conservation therapy. ( Bartelink, H; Borger, JH; Hart, A; Kemperman, H; Lebesque, J; Smitt, HS; van Dongen, J, 1994) |
| "Radiation complications included pneumonitis three of 30 (10%) and esophagitis (27%)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| "Pursuant to this, the North Central Cancer Treatment Group has developed a series of clinical trials designed to study antidotes for these pathologic processes." | 2.39 | Alleviation of cytotoxic therapy-induced normal tissue damage. ( Foote, RL; Loprinzi, CL; Michalak, J, 1995) |
| "Of the 13,499 patients with ulcerative colitis treated, 17 adult patients with ulcerative colitis and anal dysplasia and/or anal squamous cell carcinoma were included in the study: 6 had a diagnosis of anal squamous cell carcinoma, 8 had high-grade squamous intraepithelial lesions, and 3 had low-grade squamous intraepithelial lesions." | 1.62 | Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols? ( Click, B; Hull, TL; Lightner, AL; McMichael, J; Regueiro, M; Steele, SR; Vaidya, P, 2021) |
| "Our results suggest that the use of IMRT decreases acute and chronic adverse effects although reduced QoL also occurred in the IMRT group." | 1.51 | Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. ( Adeberg, S; Debus, J; Haefner, MF; Herfarth, K; Koerber, SA; Krug, D; Liermann, J; Seither, B; Slynko, A; Sterzing, F, 2019) |
| " Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
| "To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy." | 1.46 | Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017) |
| "The study included 127 gastric cancer patients, who underwent preoperative or postoperative chemoradiotherapy." | 1.43 | Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer. ( Maslyk, B; Polanowski, P; Tukiendorf, A; Wydmanski, J, 2016) |
| "Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer." | 1.42 | Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. ( Huang, JZ; Jia, XJ, 2015) |
| "Radiotherapy for rectal cancer patients may induce late pelvic complications as time progresses, and irreversible tissue changes due to radiation could disrupt the successful treatment of radiation-related complications." | 1.40 | Late complications after proctectomy in rectal cancer patients who underwent radiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2014) |
| "A 57-year-old Hispanic male with pancreatic cancer initially received 7 cycles of FOLFIRINOX followed by capecitabine with radiation therapy for 28 fractions for a total of 5,040 cGy." | 1.40 | Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer. ( Graziani, C; Hegde, S; Saif, MW, 2014) |
| "The treatment of anal cancer is based on concomitant radiotherapy and chemotherapy and is associated with a nonnegligible rate of local severe toxicities that can strongly impair the quality of life." | 1.39 | Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. ( Benezery, K; Doyen, J; Follana, P; Francois, E; Gal, J; Gérard, JP; Hannoun-Levi, JM; Ortholan, C, 2013) |
| "Locoregional treatment of inflammatory breast cancer (IBC) is crucial because local relapses may be highly symptomatic and are commonly associated with distant metastasis." | 1.38 | Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up. ( Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C, 2012) |
| "The optimal dosage and frequency of platinum-based chemoradiotherapy (CRT) regimen for treating advanced head and neck squamous cell carcinoma remains unresolved." | 1.38 | Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Fan, KY; Gogineni, H; Ha, PK; Lake, S; Levine, MA; Messing, B; Pai, SI; Saunders, JR; Tang, M; Zaboli, D; Zahurak, ML; Zinreich, ES, 2012) |
| "The records of 96 patients treated for cervical cancer from 2006 to 2010 were retrospectively reviewed." | 1.38 | Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012) |
| "Pemphigus is an autoimmune intraepidermal blistering disease mediated by autoantibodies targeting desmosomes." | 1.37 | Radiotherapy-induced pemphigus vulgaris with autoantibodies targeting a 110 kDa epidermal antigen. ( Badri, T; Benmously-Mlika, R; Fenniche, S; Hammami, H; Lachkham, A; Mokhtar, I, 2011) |
| "The global health QoL of anal cancer patients is comparable with that of the general German population, but there are specific limitations, e." | 1.37 | Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. ( Hägele, V; Mai, SK; Welzel, G; Wenz, F, 2011) |
| "Strictures were associated with tumor location (tonsil vs base of tongue; p = ." | 1.37 | Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma. ( Best, SR; Blanco, RG; Califano, JA; Ha, PK; Levine, MA; Messing, BP; Murakami, P; Pai, SI; Saunders, JR; Thompson, R; Trachta, J; Ulmer, K; Walker, M; Zinreich, ES, 2011) |
| "Forty-seven patients with head and neck cancers who underwent definitive chemoradiotherapy between December 1998 and March 2006 were reviewed retrospectively." | 1.36 | Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers. ( Kadoya, M; Koiwai, K; Sasaki, S; Shikama, N; Shinoda, A, 2010) |
| "Unknown primary head and neck cancers often require comprehensive mucosal and bilateral neck irradiation." | 1.35 | Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. ( Klem, ML; Kraus, D; Lee, NY; Mechalakos, JG; Pfister, DG; Shah, J; Shaha, A; Singh, B; Wolden, SL; Zelefsky, MJ, 2008) |
| "Every 21 days, sequential surgery of breast carcinoma, adjuvant chemotherapy FAC and irradiation." | 1.35 | [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III]. ( Bustová, I, 2009) |
| "Sixty consecutive patients treated for gastric cancer either with 3D-CRT (n = 27) and IMRT (n = 33) were evaluated." | 1.35 | Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. ( Boda-Heggemann, J; Hermes, P; Hieber, U; Hochhaus, A; Hofheinz, RD; Lohr, F; Mai, SK; Massner, B; Mennemeyer, P; Post, S; Weiss, C; Wenz, F; Wertz, H, 2009) |
| " Five cardiopulmonary toxic events of Grade 3 or greater were observed in 4 patients, Grade 5 heart failure and Grade 3 pericarditis in 1 patient, and Grade 3 myocardial infarction, Grade 3 radiation pneumonitis, and Grade 3 pleural effusion." | 1.35 | Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. ( Chin, K; Gomi, K; Ito, H; Kozuka, T; Matsuura, M; Morota, M; Oguchi, M; Yamashita, T, 2009) |
| "Fertility preservation in women with rectal cancer is feasible." | 1.35 | Fertility preservation for young women with rectal cancer--a combined approach from one referral center. ( Elizur, SE; Huang, JY; Levin, D; Meterissian, S; Tan, SL; Tulandi, T, 2009) |
| "Radiation enteritis is the main acute side-effect during pelvic irradiation." | 1.34 | Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. ( Bendahl, PO; Gunnlaugsson, A; Johnsson, A; Kjellén, E; Nilsson, P; Willner, J, 2007) |
| "This article describes a woman with metastatic upper gastrointestinal cancer who developed thoracic myelopathy unexpectedly after standard dosage and fractionation radiotherapy." | 1.33 | Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine. ( Barstis, JL; Black, AC, 2005) |
| "As patients with oesophageal cancer have a high incidence of co-morbidities including cardiac problems, the aim of this paper was to quantify the extent of cardiac radiation and discuss the influence of beam arrangement to reduce this." | 1.33 | Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer. ( Cominos, M; Cornes, P; Henrys, A; Mosleh-Shirazi, MA; Tait, D, 2005) |
| " Patients in the P+M group who received a 5-fluorouracil (5-FU) dosage of more than 3500 mg had a better 5-year local control rate than patients who received a 5-FU dosage of less than 3500 mg (p = 0." | 1.31 | Trimodal combination therapy for maxillary sinus carcinoma. ( Amagasa, T; Enomoto, S; Kishimoto, S; Miura, M; Ogura, I; Shibuya, H; Yoshimura, R, 2002) |
| "There was no clinical evidence of carcinoid syndrome." | 1.25 | 5-Hydroxyindole-secreting rectal carcinoid tumour. ( Cheetham, HD; Murray-Lyon, IM; Sandler, M; Watts, JA; Williams, R, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (12.57) | 18.7374 |
| 1990's | 19 (10.86) | 18.2507 |
| 2000's | 56 (32.00) | 29.6817 |
| 2010's | 74 (42.29) | 24.3611 |
| 2020's | 4 (2.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hennequin, C | 3 |
| Guillerm, S | 1 |
| Quero, L | 3 |
| Cheng, YK | 1 |
| Qin, QY | 1 |
| Huang, XY | 1 |
| Lan, P | 1 |
| Wang, L | 3 |
| Gao, X | 1 |
| Ma, TH | 1 |
| Smart, AC | 1 |
| Goyal, L | 1 |
| Horick, N | 1 |
| Petkovska, N | 1 |
| Zhu, AX | 1 |
| Ferrone, CR | 2 |
| Tanabe, KK | 1 |
| Allen, JN | 1 |
| Drapek, LC | 1 |
| Qadan, M | 1 |
| Murphy, JE | 1 |
| Eyler, CE | 1 |
| Ryan, DP | 2 |
| Hong, TS | 2 |
| Wo, JY | 2 |
| Sauter, M | 1 |
| Lombriser, N | 1 |
| Bütikofer, S | 1 |
| Keilholz, G | 1 |
| Kranzbühler, H | 1 |
| Heinrich, H | 1 |
| Rogler, G | 1 |
| Vavricka, SR | 1 |
| Misselwitz, B | 1 |
| Ye, W | 1 |
| Shi, L | 1 |
| Qian, L | 1 |
| Sun, Y | 1 |
| Sun, X | 1 |
| Lightner, AL | 1 |
| Vaidya, P | 1 |
| McMichael, J | 1 |
| Click, B | 1 |
| Regueiro, M | 1 |
| Steele, SR | 1 |
| Hull, TL | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Reyngold, M | 1 |
| Shi, W | 1 |
| Zhang, Z | 1 |
| Cuaron, JJ | 1 |
| Crane, CH | 3 |
| O'Reilly, EM | 1 |
| Lowery, MA | 1 |
| Yu, KH | 1 |
| Goodman, KA | 2 |
| Wu, AJ | 1 |
| Matsumoto, Y | 1 |
| Zhou, Q | 1 |
| Kamimura, K | 1 |
| Moriyama, M | 1 |
| Saijo, Y | 1 |
| Ng, M | 1 |
| Ho, H | 1 |
| Skelton, J | 1 |
| Guerrieri, M | 1 |
| Guiney, M | 1 |
| Chao, M | 1 |
| Blakey, D | 1 |
| Macleod, C | 1 |
| Amor, H | 1 |
| Subramanian, B | 1 |
| Melven, L | 1 |
| Li, Y | 2 |
| Xu, T | 1 |
| Qian, W | 1 |
| Lu, X | 1 |
| Hu, C | 1 |
| Lu, L | 1 |
| Sheng, Y | 1 |
| Zhang, G | 1 |
| OuYang, PY | 1 |
| Ge, Y | 1 |
| Xie, T | 1 |
| Chang, H | 1 |
| Deng, X | 1 |
| Wu, JQ | 1 |
| Koerber, SA | 1 |
| Seither, B | 1 |
| Slynko, A | 1 |
| Haefner, MF | 1 |
| Krug, D | 2 |
| Liermann, J | 1 |
| Adeberg, S | 1 |
| Herfarth, K | 1 |
| Debus, J | 1 |
| Sterzing, F | 1 |
| Hojo, H | 1 |
| Dohmae, T | 1 |
| Hotta, K | 1 |
| Kageyama, SI | 1 |
| Baba, H | 1 |
| Kohno, R | 1 |
| Motegi, A | 1 |
| Tsuchihara, K | 1 |
| Akimoto, T | 1 |
| Wu, L | 1 |
| Chung, YL | 2 |
| Hayashi, Y | 1 |
| Iijima, H | 1 |
| Isohashi, F | 1 |
| Tsujii, Y | 1 |
| Fujinaga, T | 1 |
| Nagai, K | 1 |
| Yoshii, S | 1 |
| Sakatani, A | 1 |
| Hiyama, S | 1 |
| Shinzaki, S | 1 |
| Makino, T | 1 |
| Yamasaki, M | 1 |
| Ogawa, K | 1 |
| Doki, Y | 1 |
| Takehara, T | 1 |
| Monma, S | 1 |
| Kato, K | 1 |
| Shouji, H | 1 |
| Okita, N | 1 |
| Takashima, A | 1 |
| Honma, Y | 1 |
| Iwasa, S | 2 |
| Hamaguchi, T | 1 |
| Yamada, Y | 1 |
| Shimada, Y | 1 |
| Boku, N | 2 |
| Nagashima, K | 1 |
| Ito, Y | 2 |
| Itami, J | 1 |
| Giuliani, A | 1 |
| Romanzi, F | 1 |
| Di Sibio, A | 1 |
| Calvisi, G | 1 |
| Lombardi, L | 1 |
| Marchese, M | 1 |
| Di Staso, M | 1 |
| Schietroma, M | 1 |
| Carlei, F | 1 |
| Romano, L | 1 |
| Nichols, RC | 1 |
| George, TJ | 1 |
| Zaiden, RA | 1 |
| Awad, ZT | 1 |
| Asbun, HJ | 1 |
| Huh, S | 1 |
| Ho, MW | 1 |
| Mendenhall, NP | 1 |
| Morris, CG | 1 |
| Hoppe, BS | 1 |
| Mayahara, H | 1 |
| Tanaka, T | 1 |
| Wong, S | 2 |
| DeFoe, SG | 1 |
| Kabolizadeh, P | 1 |
| Heron, DE | 1 |
| Beriwal, S | 1 |
| Huddart, RA | 1 |
| Hall, E | 1 |
| Hussain, SA | 1 |
| Jenkins, P | 1 |
| Rawlings, C | 1 |
| Tremlett, J | 1 |
| Crundwell, M | 1 |
| Adab, FA | 1 |
| Sheehan, D | 1 |
| Syndikus, I | 1 |
| Hendron, C | 1 |
| Lewis, R | 1 |
| Waters, R | 1 |
| James, ND | 1 |
| Doyen, J | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Ortholan, C | 2 |
| Gérard, JP | 1 |
| Hannoun-Levi, JM | 1 |
| Gal, J | 1 |
| Francois, E | 1 |
| Badakhshi, H | 2 |
| Gruen, A | 1 |
| Graf, R | 1 |
| Boehmer, D | 2 |
| Budach, V | 2 |
| Mamon, HJ | 1 |
| Blaszkowsky, LS | 1 |
| Kwak, EL | 1 |
| Tseng, YD | 1 |
| Napolitano, BN | 1 |
| Ancukiewicz, M | 1 |
| Swanson, RS | 1 |
| Lillemoe, KD | 1 |
| Fernandez-del Castillo, C | 1 |
| Becker, ET | 1 |
| Jahn, U | 1 |
| Wernecke, KD | 1 |
| Stromberger, C | 1 |
| Call, JA | 1 |
| Prendergast, BM | 1 |
| Jensen, LG | 1 |
| Ord, CB | 1 |
| Jacob, R | 1 |
| Mell, LK | 1 |
| Thomas, CR | 2 |
| Jabbour, SK | 1 |
| Miller, RC | 1 |
| Lento, W | 1 |
| Ito, T | 1 |
| Zhao, C | 1 |
| Harris, JR | 1 |
| Huang, W | 2 |
| Jiang, C | 1 |
| Owzar, K | 1 |
| Piryani, S | 1 |
| Racioppi, L | 1 |
| Chao, N | 1 |
| Reya, T | 1 |
| Kim, SH | 1 |
| Kim, JH | 2 |
| Jung, SH | 1 |
| Trip, AK | 1 |
| Nijkamp, J | 1 |
| van Tinteren, H | 1 |
| Cats, A | 1 |
| Boot, H | 1 |
| Jansen, EP | 1 |
| Verheij, M | 1 |
| Graziani, C | 1 |
| Hegde, S | 1 |
| Saif, MW | 1 |
| Li, ZY | 1 |
| Li, ZW | 1 |
| Li, YH | 1 |
| Sun, YS | 1 |
| Ji, JF | 1 |
| Gu, J | 1 |
| Cai, Y | 1 |
| Troussier, I | 1 |
| Huguet, F | 1 |
| Servagi-Vernat, S | 1 |
| Benahim, C | 1 |
| Khalifa, J | 1 |
| Darmon, I | 1 |
| Krebs, L | 1 |
| Dejean, C | 1 |
| Fenoglietto, P | 1 |
| Vieillot, S | 1 |
| Bensadoun, RJ | 1 |
| Thariat, J | 1 |
| Osti, MF | 1 |
| Nicosia, L | 1 |
| Agolli, L | 1 |
| Gentile, G | 1 |
| Falco, T | 1 |
| Bracci, S | 1 |
| Di Nardo, F | 1 |
| Minniti, G | 1 |
| De Sanctis, V | 1 |
| Valeriani, M | 1 |
| Maglio, M | 1 |
| Borro, M | 1 |
| Simmaco, M | 1 |
| Enrici, RM | 1 |
| Du, CR | 1 |
| Ying, HM | 1 |
| Kong, FF | 1 |
| Zhai, RP | 1 |
| Hu, CS | 1 |
| Champ, CE | 1 |
| Smith, RP | 1 |
| Korytova, LI | 1 |
| Sandalevskaya, AG | 1 |
| Krasnikoval, VG | 1 |
| Korytov, OV | 1 |
| Meshechkin, AV | 1 |
| Voong, KR | 1 |
| Rashid, A | 1 |
| Minsky, BD | 2 |
| Krishnan, S | 2 |
| Yao, JC | 1 |
| Wolff, RA | 1 |
| Skibber, JM | 2 |
| Feig, BW | 2 |
| Chang, GJ | 2 |
| Das, P | 2 |
| Jia, XJ | 1 |
| Huang, JZ | 1 |
| Wydmanski, J | 1 |
| Polanowski, P | 1 |
| Tukiendorf, A | 1 |
| Maslyk, B | 1 |
| Nakata, Y | 1 |
| Ijichi, K | 1 |
| Hanai, N | 1 |
| Nishikawa, D | 1 |
| Suzuki, H | 1 |
| Hirakawa, H | 1 |
| Kodaira, T | 2 |
| Fujimoto, Y | 1 |
| Fujii, T | 2 |
| Miyazaki, T | 1 |
| Shimizu, T | 1 |
| Hasegawa, Y | 1 |
| Shaib, WL | 1 |
| Hawk, N | 1 |
| Cassidy, RJ | 1 |
| Chen, Z | 1 |
| Zhang, C | 1 |
| Brutcher, E | 1 |
| Kooby, D | 1 |
| Maithel, SK | 1 |
| Sarmiento, JM | 1 |
| Landry, J | 1 |
| El-Rayes, BF | 1 |
| Chen, NX | 1 |
| Zhang, XX | 1 |
| Chen, L | 1 |
| Wang, JL | 1 |
| Yan, F | 1 |
| Ma, L | 1 |
| Qin, Q | 1 |
| Ma, T | 1 |
| Deng, Y | 1 |
| Zheng, J | 1 |
| Zhou, Z | 1 |
| Wang, H | 1 |
| Wang, J | 1 |
| Häfner, MF | 1 |
| Franco, P | 1 |
| Ragona, R | 1 |
| Arcadipane, F | 1 |
| Mistrangelo, M | 1 |
| Cassoni, P | 1 |
| Rondi, N | 1 |
| Morino, M | 1 |
| Racca, P | 1 |
| Ricardi, U | 1 |
| Rödel, C | 1 |
| Fokas, E | 1 |
| Lee, AW | 1 |
| Ng, WT | 1 |
| Hung, WM | 1 |
| Choi, CW | 1 |
| Tung, R | 1 |
| Ling, YH | 1 |
| Cheng, PT | 1 |
| Yau, TK | 1 |
| Chang, AT | 1 |
| Leung, SK | 1 |
| Lee, MC | 1 |
| Bentzen, SM | 1 |
| Elizur, SE | 1 |
| Tulandi, T | 1 |
| Meterissian, S | 1 |
| Huang, JY | 1 |
| Levin, D | 1 |
| Tan, SL | 1 |
| Myerson, RJ | 3 |
| Outlaw, ED | 1 |
| Chang, A | 1 |
| Birnbaum, EH | 2 |
| Fleshman, JW | 2 |
| Grigsby, PW | 2 |
| Kodner, IJ | 2 |
| Malayapa, RS | 1 |
| Mutch, MG | 1 |
| Parikh, P | 1 |
| Picus, J | 3 |
| Tan, BR | 1 |
| Morota, M | 1 |
| Gomi, K | 1 |
| Kozuka, T | 1 |
| Chin, K | 1 |
| Matsuura, M | 1 |
| Oguchi, M | 1 |
| Ito, H | 1 |
| Yamashita, T | 1 |
| Boda-Heggemann, J | 1 |
| Hofheinz, RD | 1 |
| Weiss, C | 1 |
| Mennemeyer, P | 1 |
| Mai, SK | 3 |
| Hermes, P | 1 |
| Wertz, H | 1 |
| Post, S | 1 |
| Massner, B | 1 |
| Hieber, U | 1 |
| Hochhaus, A | 1 |
| Wenz, F | 3 |
| Lohr, F | 1 |
| Kim, DH | 1 |
| Wang-Chesebro, A | 1 |
| Weinberg, V | 1 |
| Pouliot, J | 1 |
| Chen, LM | 1 |
| Speight, J | 1 |
| Littell, R | 1 |
| Hsu, IC | 1 |
| Bustová, I | 1 |
| Lee, N | 1 |
| Harris, J | 1 |
| Garden, AS | 2 |
| Straube, W | 1 |
| Glisson, B | 1 |
| Xia, P | 1 |
| Bosch, W | 1 |
| Morrison, WH | 2 |
| Quivey, J | 1 |
| Thorstad, W | 1 |
| Jones, C | 1 |
| Ang, KK | 2 |
| Robertson, JM | 1 |
| Söhn, M | 1 |
| Yan, D | 1 |
| Delclos, ME | 1 |
| Rodriguez-Bigas, MA | 2 |
| Eng, C | 1 |
| Bedi, M | 1 |
| Li, BS | 1 |
| Zhou, T | 1 |
| Wang, ZT | 1 |
| Li, HS | 1 |
| Sun, HF | 1 |
| Zhang, ZC | 1 |
| Lin, HQ | 1 |
| Wei, YM | 1 |
| Gong, HY | 1 |
| Yi, Y | 1 |
| Wang, LY | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Tribius, S | 2 |
| Kronemann, S | 2 |
| Kilic, Y | 1 |
| Schroeder, U | 2 |
| Hakim, S | 1 |
| Schild, SE | 2 |
| Rades, D | 2 |
| Wolff, HA | 3 |
| Gaedcke, J | 2 |
| Jung, K | 2 |
| Hermann, RM | 2 |
| Rothe, H | 1 |
| Schirmer, M | 2 |
| Liersch, T | 1 |
| Herrmann, MKA | 1 |
| Hennies, S | 3 |
| Rave-Fränk, M | 4 |
| Hess, CF | 4 |
| Christiansen, H | 3 |
| Yang, GY | 1 |
| May, KS | 1 |
| Iyer, RV | 1 |
| Chandrasekhar, R | 1 |
| Wilding, GE | 1 |
| McCloskey, SA | 1 |
| Khushalani, NI | 1 |
| Yendamuri, SS | 1 |
| Gibbs, JF | 1 |
| Fakih, M | 1 |
| Semikopov, KV | 1 |
| Vazhenin, AV | 1 |
| Nadvikova, EA | 1 |
| Lukina, EIu | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Kazic, N | 1 |
| Hakim, SG | 1 |
| Dunst, J | 2 |
| Koiwai, K | 1 |
| Shikama, N | 1 |
| Sasaki, S | 1 |
| Shinoda, A | 1 |
| Kadoya, M | 1 |
| Benoit, A | 1 |
| Ducray, F | 1 |
| Cartalat-Carel, S | 1 |
| Psimaras, D | 1 |
| Ricard, D | 1 |
| Honnorat, J | 1 |
| Chon, YE | 1 |
| Seong, J | 1 |
| Kim, BK | 1 |
| Cha, J | 1 |
| Kim, SU | 1 |
| Park, JY | 1 |
| Ahn, SH | 1 |
| Han, KH | 1 |
| Chon, CY | 1 |
| Shin, SK | 1 |
| Kim, DY | 1 |
| Isaev, PA | 1 |
| Medvedev, VS | 1 |
| Pasov, VV | 1 |
| Semin, DIu | 1 |
| Derbugov, DN | 1 |
| Pol'kin, VV | 1 |
| Terekhov, OV | 1 |
| Herrmann, MK | 2 |
| Eickelmann, D | 1 |
| Virsik, P | 1 |
| Ghadimi, M | 2 |
| Best, SR | 2 |
| Ha, PK | 2 |
| Blanco, RG | 2 |
| Saunders, JR | 2 |
| Zinreich, ES | 2 |
| Levine, MA | 2 |
| Pai, SI | 2 |
| Walker, M | 1 |
| Trachta, J | 1 |
| Ulmer, K | 1 |
| Murakami, P | 1 |
| Thompson, R | 1 |
| Califano, JA | 2 |
| Messing, BP | 1 |
| Bourgier, C | 1 |
| Pessoa, EL | 1 |
| Dunant, A | 1 |
| Heymann, S | 1 |
| Spielmann, M | 1 |
| Uzan, C | 1 |
| Mathieu, MC | 1 |
| Arriagada, R | 1 |
| Marsiglia, H | 1 |
| Welzel, G | 1 |
| Hägele, V | 1 |
| Shien, K | 1 |
| Yamashita, M | 1 |
| Okazaki, M | 1 |
| Suehisa, H | 1 |
| Sawada, S | 1 |
| Miyoshi, S | 1 |
| Yen, SH | 1 |
| Wang, LW | 1 |
| Lin, YH | 1 |
| Jen, YM | 1 |
| Wu, J | 1 |
| Chen, EL | 1 |
| Weng, XR | 1 |
| Zehentmayr, F | 1 |
| Wolf, M | 1 |
| Weissenborn, Y | 1 |
| Feldmann, HJ | 1 |
| Belka, C | 1 |
| Schirmer, MA | 1 |
| Mergler, CP | 1 |
| Conradi, LC | 1 |
| Jo, P | 1 |
| Beissbarth, T | 1 |
| Becker, H | 1 |
| Brockmöller, J | 1 |
| Vande Walle, C | 1 |
| Ceelen, WP | 1 |
| Boterberg, T | 1 |
| Vande Putte, D | 1 |
| Van Nieuwenhove, Y | 1 |
| Varin, O | 1 |
| Pattyn, P | 1 |
| Engels, B | 1 |
| Tournel, K | 1 |
| Everaert, H | 1 |
| Hoorens, A | 1 |
| Sermeus, A | 1 |
| Christian, N | 1 |
| Storme, G | 1 |
| Verellen, D | 1 |
| De Ridder, M | 1 |
| Badri, T | 1 |
| Hammami, H | 1 |
| Lachkham, A | 1 |
| Benmously-Mlika, R | 1 |
| Mokhtar, I | 1 |
| Fenniche, S | 1 |
| Zhang, M | 1 |
| Xu, HD | 1 |
| Pan, SD | 1 |
| Lin, S | 1 |
| Yue, JH | 1 |
| Liu, JR | 1 |
| Rasouli, HA | 1 |
| Moghadam, MM | 1 |
| Tabatabaiefar, M | 1 |
| Taslimi, F | 1 |
| Sheybani, KM | 1 |
| Alidoosti, A | 1 |
| Ameri, A | 1 |
| Fadavi, P | 1 |
| Aref, S | 1 |
| Fan, KY | 1 |
| Gogineni, H | 1 |
| Zaboli, D | 1 |
| Lake, S | 1 |
| Zahurak, ML | 1 |
| Tang, M | 1 |
| Messing, B | 1 |
| Yi, SK | 1 |
| Mak, W | 1 |
| Yang, CC | 1 |
| Liu, T | 1 |
| Cui, J | 1 |
| Chen, AM | 1 |
| Purdy, JA | 1 |
| Monjazeb, AM | 1 |
| Do, L | 1 |
| Goto, Y | 1 |
| Fuwa, N | 1 |
| Mizoguchi, N | 1 |
| Nakahara, R | 1 |
| Nomura, M | 1 |
| Tomita, N | 1 |
| Tachibana, H | 1 |
| Kachnic, LA | 1 |
| Winter, K | 1 |
| Goodyear, MD | 1 |
| Willins, J | 1 |
| Esthappan, J | 1 |
| Haddock, MG | 1 |
| Rotman, M | 1 |
| Parikh, PJ | 1 |
| Safran, H | 1 |
| Willett, CG | 1 |
| Banerjee, R | 1 |
| Chakraborty, S | 1 |
| Nygren, I | 1 |
| Sinha, R | 1 |
| Duchemann, B | 1 |
| Duchemain, B | 1 |
| Baruch-Hennequin, V | 1 |
| Rivera, S | 1 |
| John, M | 2 |
| Flam, M | 1 |
| Palma, N | 1 |
| Shakespeare, TP | 1 |
| Dwyer, M | 1 |
| Mukherjee, R | 1 |
| Yeghiaian-Alvandi, R | 1 |
| Gebski, V | 1 |
| Myerson, R | 3 |
| Zobeiri, I | 1 |
| Birnbaum, E | 1 |
| Dietz, D | 1 |
| Fleshman, J | 1 |
| Kodner, I | 1 |
| Ratkin, G | 1 |
| Lorvidhaya, V | 1 |
| Chitapanarux, I | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Micke, O | 1 |
| Bruns, F | 1 |
| Mücke, R | 1 |
| Schäfer, U | 1 |
| Glatzel, M | 1 |
| DeVries, AF | 1 |
| Schönekaes, K | 1 |
| Kisters, K | 1 |
| Büntzel, J | 1 |
| Chua, DT | 1 |
| Sham, JS | 2 |
| Kwong, PW | 2 |
| Hung, KN | 1 |
| Leung, LH | 2 |
| Vuong, T | 1 |
| Devic, S | 1 |
| Belliveau, P | 1 |
| Muanza, T | 1 |
| Hegyi, G | 1 |
| Mukherjee, S | 1 |
| Aston, D | 1 |
| Minett, M | 1 |
| Brewster, AE | 1 |
| Crosby, TD | 1 |
| Alvarez, E | 1 |
| Fey, EG | 1 |
| Valax, P | 1 |
| Yim, Z | 1 |
| Peterson, JD | 1 |
| Mesri, M | 1 |
| Jeffers, M | 1 |
| Dindinger, M | 1 |
| Twomlow, N | 1 |
| Ghatpande, A | 1 |
| LaRochelle, WJ | 1 |
| Sonis, ST | 1 |
| Lichenstein, HS | 1 |
| JUSTIN-BESANCON, L | 1 |
| GRIVAUX, M | 1 |
| CORNET, A | 1 |
| TOURNEUR, R | 1 |
| GUERRE, J | 1 |
| Schmidberger, H | 1 |
| Kim, S | 1 |
| Hille, A | 1 |
| Pradier, O | 1 |
| Sykes, AJ | 1 |
| Slevin, NJ | 1 |
| MacDougall, RH | 1 |
| Ironside, JA | 1 |
| Mais, KL | 1 |
| Milano, MT | 1 |
| Chmura, SJ | 1 |
| Garofalo, MC | 1 |
| Rash, C | 1 |
| Roeske, JC | 1 |
| Connell, PP | 1 |
| Kwon, OH | 1 |
| Jani, AB | 1 |
| Heimann, R | 1 |
| Lerouge, D | 1 |
| Touboul, E | 1 |
| Lefranc, JP | 1 |
| Uzan, S | 1 |
| Jannet, D | 1 |
| Moureau-Zabotto, L | 1 |
| Genestie, C | 1 |
| Antoine, M | 1 |
| Jamali, M | 1 |
| Ernst-Stecken, A | 1 |
| Grabenbauer, G | 1 |
| Iro, H | 1 |
| Plasswilm, L | 1 |
| Sauer, R | 2 |
| Franchin, G | 1 |
| Vaccher, E | 1 |
| Gobitti, C | 1 |
| Minatel, E | 1 |
| Politi, D | 1 |
| Talamini, R | 1 |
| Di Gennaro, G | 1 |
| Savignano, G | 1 |
| Trovò, MG | 1 |
| Tirelli, U | 1 |
| Barzan, L | 1 |
| Dörr, W | 1 |
| Bässler, S | 1 |
| Reichel, S | 1 |
| Spekl, K | 1 |
| Chang, PY | 1 |
| Chao, TY | 1 |
| Dai, MS | 1 |
| Yom, SS | 1 |
| Machtay, M | 1 |
| Biel, MA | 1 |
| Sinard, RJ | 1 |
| El-Naggar, AK | 1 |
| Weber, RS | 1 |
| Rosenthal, DI | 1 |
| Kwong, DL | 1 |
| Cheng, AC | 1 |
| Ng, WM | 1 |
| Lui, WM | 1 |
| Yau, CC | 1 |
| Wu, PM | 1 |
| Wei, W | 1 |
| Au, G | 1 |
| Barstis, JL | 1 |
| Black, AC | 1 |
| Cominos, M | 1 |
| Mosleh-Shirazi, MA | 1 |
| Tait, D | 1 |
| Henrys, A | 1 |
| Cornes, P | 1 |
| Wals, A | 1 |
| Contreras, J | 1 |
| Macías, J | 1 |
| Fortes, I | 1 |
| Rivas, D | 1 |
| González, P | 1 |
| Herruzo, I | 1 |
| Rapidis, AD | 1 |
| Trichas, M | 1 |
| Stavrinidis, E | 1 |
| Roupakia, A | 1 |
| Ioannidou, G | 1 |
| Kritselis, G | 1 |
| Liossi, P | 1 |
| Giannakouras, G | 1 |
| Douzinas, EE | 1 |
| Katsilieris, I | 1 |
| Bibeau, F | 1 |
| Azria, D | 1 |
| Chateau, MC | 1 |
| Borrelly, C | 1 |
| Ychou, M | 1 |
| Quenet, F | 1 |
| Rouanet, P | 1 |
| Kendal, WS | 1 |
| Jonker, D | 1 |
| Stern, H | 1 |
| Moyana, T | 1 |
| Patonay, P | 1 |
| Naszály, A | 1 |
| Mayer, A | 1 |
| Choi, CH | 1 |
| Lee, JW | 1 |
| Kim, TJ | 1 |
| Kim, WY | 1 |
| Nam, HR | 1 |
| Kim, BG | 1 |
| Huh, SJ | 1 |
| Lee, JH | 1 |
| Bae, DS | 1 |
| Rischke, HC | 1 |
| Momm, F | 1 |
| Henke, M | 1 |
| Wiech, T | 1 |
| Frommhold, H | 1 |
| Solano, JM | 1 |
| Bakri, SJ | 1 |
| Pulido, JS | 1 |
| Gunnlaugsson, A | 1 |
| Kjellén, E | 1 |
| Nilsson, P | 1 |
| Bendahl, PO | 1 |
| Willner, J | 1 |
| Johnsson, A | 1 |
| Klem, ML | 1 |
| Mechalakos, JG | 1 |
| Wolden, SL | 1 |
| Zelefsky, MJ | 2 |
| Singh, B | 1 |
| Kraus, D | 1 |
| Shaha, A | 1 |
| Shah, J | 1 |
| Pfister, DG | 1 |
| Lee, NY | 1 |
| Brunner, TB | 1 |
| Rupp, A | 1 |
| Melzner, W | 1 |
| Grabenbauer, GG | 1 |
| Livi, L | 1 |
| Saieva, C | 1 |
| Borghesi, S | 1 |
| Paoletti, L | 1 |
| Meattini, I | 1 |
| Rampini, A | 1 |
| Petrucci, A | 1 |
| Scoccianti, S | 1 |
| Paiar, F | 1 |
| Cataliotti, L | 1 |
| Leonulli, BG | 1 |
| Bianchi, S | 1 |
| Biti, GP | 1 |
| Konski, A | 1 |
| Garcia, M | 1 |
| Krieg, R | 1 |
| Pinover, W | 1 |
| Willett, C | 1 |
| Habeshaw, T | 1 |
| Adam, JS | 1 |
| Kirk, J | 1 |
| Hainsworth, JD | 1 |
| Malcolm, A | 1 |
| Johnson, DH | 1 |
| Burnett, LS | 1 |
| Jones, HW | 1 |
| Greco, FA | 1 |
| Maisin, H | 2 |
| Anckaert, MA | 2 |
| De Coster, BM | 2 |
| Bean, DJ | 1 |
| Rees, RS | 1 |
| O'Leary, JP | 1 |
| Lynch, JB | 1 |
| Benoldi, D | 1 |
| Pezzarossa, E | 1 |
| Alinovi, A | 1 |
| Labrini, G | 1 |
| Marcheselli, W | 1 |
| de Panfilis, G | 1 |
| Manfredi, G | 1 |
| Bounous, G | 1 |
| Loprinzi, CL | 1 |
| Foote, RL | 1 |
| Michalak, J | 1 |
| Borger, JH | 1 |
| Kemperman, H | 1 |
| Smitt, HS | 1 |
| Hart, A | 1 |
| van Dongen, J | 1 |
| Lebesque, J | 1 |
| Bartelink, H | 1 |
| Witzigmann, H | 1 |
| Sagasser, J | 1 |
| Meyer, FM | 1 |
| Witte, J | 1 |
| Park, TK | 1 |
| Lee, SK | 1 |
| Kim, SN | 1 |
| Hwang, TS | 1 |
| Kim, GE | 1 |
| Suh, CO | 1 |
| Loh, JK | 1 |
| Ohtsu, A | 1 |
| Yoshida, S | 1 |
| Miyata, Y | 1 |
| Hosokawa, K | 1 |
| Koba, I | 1 |
| Shimizu, W | 1 |
| Ogino, T | 1 |
| Lin, JC | 1 |
| Ho, ES | 1 |
| Jan, JS | 1 |
| Yang, CH | 1 |
| Liu, FS | 1 |
| Hareyama, M | 1 |
| Nagakura, H | 1 |
| Tamakawa, M | 1 |
| Hyodo, K | 1 |
| Asakura, K | 1 |
| Horikoshi, T | 1 |
| Tanaka, S | 1 |
| Imai, K | 1 |
| Hattori, A | 1 |
| Oouchi, A | 1 |
| Shido, M | 1 |
| Koshiba, H | 1 |
| Sakata, K | 1 |
| Morita, K | 1 |
| Rakovitch, E | 1 |
| Fyles, AW | 1 |
| Pintilie, M | 1 |
| Leung, PM | 1 |
| Smith, TJ | 1 |
| Ryan, LM | 1 |
| Douglass, HO | 1 |
| Haller, DG | 1 |
| Dayal, Y | 1 |
| Kirkwood, J | 1 |
| Tormey, DC | 1 |
| Schutt, AJ | 1 |
| Hinson, J | 1 |
| Sischy, B | 1 |
| Chaney, AW | 1 |
| Eifel, PJ | 1 |
| Logsdon, MD | 1 |
| Morris, M | 1 |
| Wharton, JT | 1 |
| Glisson, BS | 1 |
| Lippman, SM | 1 |
| Byers, RM | 1 |
| Geara, F | 1 |
| Clayman, GL | 1 |
| Shin, DM | 1 |
| Callender, DL | 1 |
| Khuri, FR | 1 |
| Goepfert, H | 1 |
| Hong, WK | 1 |
| Peters, LJ | 1 |
| Joseph, CD | 1 |
| Praveenkumar, V | 1 |
| Kuttan, G | 1 |
| Kuttan, R | 1 |
| Liao, Z | 1 |
| Strom, EA | 1 |
| Buzdar, AU | 1 |
| Singletary, SE | 1 |
| Hunt, K | 1 |
| Allen, PK | 1 |
| McNeese, MD | 1 |
| Alektiar, KM | 1 |
| Paty, PB | 1 |
| Guillem, J | 1 |
| Saltz, LB | 1 |
| Cohen, AM | 1 |
| Waddell, BE | 1 |
| Lee, RJ | 1 |
| Weber, TK | 1 |
| Petrelli, NJ | 1 |
| Semlin, S | 1 |
| Pigorsch, S | 1 |
| Müller, AC | 1 |
| Reese, T | 1 |
| Choi, EK | 1 |
| Kim, SB | 1 |
| Park, SI | 1 |
| Kim, DK | 1 |
| Song, HY | 1 |
| Jung, HY | 1 |
| Min, YI | 1 |
| Valentini, V | 1 |
| Cellini, N | 1 |
| Coco, C | 1 |
| Gambacorta, MA | 1 |
| Genovesi, D | 1 |
| Ratkin, GA | 1 |
| Read, TE | 1 |
| Tjandra, JJ | 1 |
| Reading, DM | 1 |
| McLachlan, SA | 1 |
| Gunn, IF | 1 |
| Green, MD | 1 |
| McLaughlin, SJ | 1 |
| Millar, JL | 1 |
| Pedersen, JS | 1 |
| El-Weshi, A | 1 |
| Khafaga, Y | 1 |
| Allam, A | 1 |
| Mosseri, V | 1 |
| Ibrahim, E | 1 |
| El-Serafi, M | 1 |
| El-Badawi, S | 1 |
| Heydon, K | 1 |
| Mutch, DG | 1 |
| Kim, RY | 1 |
| Eifel, P | 1 |
| Munker, R | 1 |
| Purmale, L | 1 |
| Aydemir, U | 1 |
| Reitmeier, M | 1 |
| Pohlmann, H | 1 |
| Schorer, H | 1 |
| Hartenstein, R | 1 |
| Grieger, J | 1 |
| Lachmann, R | 1 |
| Bohrer, M | 1 |
| Tiefenbacher, U | 1 |
| Yoshimura, R | 1 |
| Shibuya, H | 1 |
| Ogura, I | 1 |
| Miura, M | 1 |
| Amagasa, T | 1 |
| Enomoto, S | 1 |
| Kishimoto, S | 1 |
| Friedman, M | 1 |
| Cassidy, M | 1 |
| Levine, M | 1 |
| Phillips, T | 1 |
| Spivack, S | 1 |
| Resser, KJ | 1 |
| Danjoux, CE | 2 |
| Catton, GE | 1 |
| Sponzo, RW | 1 |
| Cunningham, TJ | 1 |
| Caradonna, RR | 1 |
| Antemann, R | 1 |
| Sommer, K | 1 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Krüll, A | 1 |
| Hübener, KH | 1 |
| Birk, S | 1 |
| Gabrail, NY | 1 |
| Harrison, BR | 1 |
| Sunwoo, YC | 1 |
| Berek, JS | 1 |
| Heaps, JM | 1 |
| Fu, YS | 1 |
| Juillard, GJ | 1 |
| Hacker, NF | 1 |
| Seydel, HG | 1 |
| Stablein, DM | 1 |
| Leichman, LP | 1 |
| Kinzie, JJ | 1 |
| Thomas, PR | 1 |
| Recine, D | 1 |
| Rowland, K | 1 |
| Reddy, S | 1 |
| Lee, MS | 1 |
| Bonomi, P | 1 |
| Taylor, S | 1 |
| Faber, LP | 1 |
| Warren, W | 1 |
| Kittle, CF | 1 |
| Hendrickson, FR | 1 |
| Vakker, AV | 1 |
| Puchinina, EA | 1 |
| Lokich, J | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Langer, M | 1 |
| Flores-Genger, H | 1 |
| Sevelda, P | 1 |
| Fiegl, J | 1 |
| Ringler, M | 1 |
| Kubista, E | 1 |
| Gez, E | 1 |
| Sulkes, A | 1 |
| Peretz, T | 1 |
| Weshler, Z | 1 |
| Sakai, S | 1 |
| Kubo, T | 1 |
| Mori, N | 1 |
| Itoh, M | 1 |
| Miyaguchi, M | 1 |
| Kitaoku, S | 1 |
| Sakata, Y | 1 |
| Fuchihata, H | 1 |
| Jingu, K | 1 |
| Nitter, L | 1 |
| Levantine, A | 1 |
| Almeyda, J | 1 |
| Murray-Lyon, IM | 1 |
| Sandler, M | 1 |
| Cheetham, HD | 1 |
| Watts, JA | 1 |
| Williams, R | 1 |
| Tsoĭ, AI | 1 |
| Dement'eva, NI | 1 |
| Sulaeva, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer[NCT00889187] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to Excess toxicity was identified intraoperatively) | ||
| Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-05-09 | Recruiting | ||
| Phase I Study of Stereotactic Body Radiation Therapy and 5-Fluorouracil, Oxaliplatin and Irinotecan (FOLFIRINOX) in the Neoadjuvant Therapy of Pancreatic Cancer[NCT01446458] | Phase 1 | 13 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer[NCT01211210] | Phase 2/Phase 3 | 495 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480] | 250 participants (Anticipated) | Interventional | 2018-12-17 | Recruiting | |||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| A Phase II Study Of Intensity Modulated Radiation Therapy (IMRT) +/- Chemotherapy For Nasopharyngeal Cancer[NCT00057785] | Phase 2 | 68 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)[NCT02907710] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-10-31 | Not yet recruiting | ||
| Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial[NCT04992988] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-06-28 | Recruiting | ||
| Toripalimab in Combination With Concurrent Chemoradiotherapy for Local-regional Recurrent Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial[NCT04376866] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-28 | Recruiting | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| Quarterback 22: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer[NCT02945631] | 43 participants (Actual) | Interventional | 2016-04-25 | Active, not recruiting | |||
| The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer[NCT01706939] | Phase 3 | 23 participants (Actual) | Interventional | 2012-09-01 | Active, not recruiting | ||
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| The Role of Sodium Selenite Supplementation in Patients With Locally Advanced Head and Neck Cancer Undergoing Concurrent Chemoradiotherapy[NCT05451576] | 60 participants (Anticipated) | Interventional | 2020-08-12 | Recruiting | |||
| trūFreeze® Spray Cryotherapy Patient Registry[NCT01802203] | 275 participants (Actual) | Observational [Patient Registry] | 2013-04-30 | Completed | |||
| Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to unable to obtain funding to conduct study) | |||
| Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713] | Phase 3 | 310 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DLT occurring within 3 weeks of the start of chemoradiation therapy was defined as: Grade 3 non-hematologic or hematologic toxicity requiring interruption of >7 days (d) of chemo or >3d chemoradiation; Grade 4 non-hematologic; Grade 4 neutropenia or thrombocytopenia; Treatment-related death; Delays in surgery >3 weeks due to treatment-related toxicity. A 30% increase in any surgical complication rate beyond those previously established rates (readmission rate: 16%; pancreatic fistula/intra-abdominal abscess/infection rate: 27%, major intra-abdominal bleeding requiring return to OR: 1.6%, delayed gastric emptying: 4.4%, and superficial wound infection rate: 8%) was also considered a DLT. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | patients with DLT (Number) |
|---|---|
| Phase 1 Cohort 1: Photon Rad (30 Gy/12 Days)+Capecitabine | 0 |
| Phase I Cohort 2: Photon Rad (25 Gy/11 Days)+Capecitabine | 0 |
| Phase I Cohort 3: Photon Rad (25 Gy/5 Days)+Capecitabine | 0 |
Neoadjuvant short-course photon radiation therapy MTD in combination with capecitabine 825 mg/m2 orally BID for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy is determined by the number of patients who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If none of 3 initial patients or only 1 of 6 patients have a DLT on dose level 3 then 6 additional patients are treated at this dose. If during this expansion, the rate of DLT exceeds 30% then the next lower dose level is declared the MTD. If no DLTs are observed, the MTD is not reached. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy
| Intervention | Gy per fraction (Number) |
|---|---|
| All Phase I: Photon Rad+Capecitabine | NA |
Patients scored by the study chairs as no variation or minor variation were considered compliant, while patients scored as major variation or inevaluable were considered non-compliant. The number being reported is the number non-compliant. A compliance rate of 90% was targeted with 75% or lower being considered unacceptable. Fifty-seven patients were required with types I and II error rates both 0.10. If 10 or more patients out of 57 were non-compliant, the treatment would be unacceptable, per a two-stage Fleming multiple testing procedure. (NCT00057785)
Timeframe: From start of treatment to end of treatment
| Intervention | participants (Number) |
|---|---|
| IMRT +/- Chemotherapy | 9 |
To determine biomarkers predictive of failure with either reduced or standard dose radiotherapy. (NCT01706939)
Timeframe: at 5 years
| Intervention | biomarkers (Number) |
|---|---|
| Reduced Dose Radiation | 0 |
| Standard Dose Radiation | 0 |
MDADI is a questionnaire of 20 questions and contains a global subscale, and three other categories of questions (emotional, functional, and physical). The scores are summed and a mean score is calculated. This mean score was multiplied by 20 to obtain a score, with a range of 0 (extremely low functioning) to 100 (high functioning). Thus, a higher MDADI score represented better day-to-day functioning and better QOL. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | -8.12 |
| Standard Dose Radiation | -8.93 |
XQ is a nine questions survey developed specifically for xerostomia symptoms. The scores are summed and a mean score is calculated on a scale of 0 (low xerostomia interference) to 10 (high xerostomia interference). A lower or negative score reflects a better quality of life compared to baseline. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) |
|---|---|
| Reduced Dose Radiation | 2.18 |
| Standard Dose Radiation | 4.38 |
Number of participants with acute toxicity treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 3 |
| Standard Dose Radiation | 1 |
Local-regional control (LRC) at 3 years in patients with advanced HPV related oropharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
Overall Survival (OS) 5 years treated with reduced or standard dose CRT. (NCT01706939)
Timeframe: at 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Reduced Dose Radiation | 10 |
| Standard Dose Radiation | 7 |
The EORTC Head and Neck module was specifically designed and validated for head and neck cancer patients. This 35-item questionnaire contains 7 symptom scales (pain, swallowing, senses, speech, social eating, social contact, and sexuality), 6 single-item scales (difficulties of teeth, mouth opening, dry mouth, sticky saliva, coughing, and feeling ill), and 5 items about the additional use of pain medicine, nutritional supplements, and feeding tube and changes in body weight. All items were transformed to scales from 0 to 100, and divided into respective sub-scores of global health (GHS), functional (FS), and symptom scale (SS). Subscales from 0-100. A high score on global health and functional scale represents a better level of functioning, whereas a high score on a symptom scale and head and neck module indicates more severe symptoms. (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| EORTC GHS | EORTC FS | EORTC SS | EORTC HN | |
| Reduced Dose Radiation | 5.95 | 5.14 | -3.91 | -2.80 |
| Standard Dose Radiation | -30.56 | -6.33 | 14.97 | 8.97 |
"MD Anderson Symptom Inventory Symptom Inventory and Severity (MDASI-HN SI and SS) MDASI Head and Neck is a site-specific MDASI module which includes the core MDASI 13 symptom severity items (SS) and 6 symptom interference items (SI), alongside 9 items relevant to head and neck cancer. The scores are summed and a mean score is calculated on a scale of 0 (low severity or interference) to 10 (high severity or complete interference). In order to calculate the mean score, a majority of the subscale's items must have been completed.~A lower or negative score reflects a better quality of life compared to baseline." (NCT01706939)
Timeframe: Baseline and 5 years
| Intervention | score on a scale (Mean) | |
|---|---|---|
| MDASI-HN SI | MDASI-HN SS | |
| Reduced Dose Radiation | 0.64 | 0.52 |
| Standard Dose Radiation | 1.56 | 1.48 |
Progression free survival (PFS) at 5 years in patients with advanced HPV related oropharynx cancer, nasopharynx cancer or unknown primary treated with reduced or standard dose radiation. (NCT01706939)
Timeframe: at 3 and 5 years
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| at 3 years | at 5 years | |
| Reduced Dose Radiation | 10 | 10 |
| Standard Dose Radiation | 7 | 7 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
7 reviews available for fluorouracil and Injuries, Radiation
| Article | Year |
|---|---|
Combination of chemotherapy and radiotherapy: A thirty years evolution.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemoradiotherapy; | 2019 |
[Brachytherapy for oesophageal cancer].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2013 |
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Confidence | 2015 |
Does radiation prevent 5-fluorouracil-induced colitis in the early phase of radiochemotherapy? A case report and literature review.
Topics: Adult; Antineoplastic Agents; Colitis; Fluorouracil; Humans; Male; Radiation Injuries; Radiotherapy, | 2007 |
Alleviation of cytotoxic therapy-induced normal tissue damage.
Topics: Chlorhexidine; Clinical Trials as Topic; Cryotherapy; Dermatitis; Esophagitis; Eye Diseases; Fluorou | 1995 |
Retropharyngeal abscess after radiation therapy and cis-platinum, 5-fluorouracil treatment for nasopharyngeal carcinoma with collagen disease: report of two patients and a review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Collagen Diseas | 1996 |
Drug reactions. XXIV. Cutaneous reactions to cytostatic agents.
Topics: Alopecia; Aminopterin; Antineoplastic Agents; Asparaginase; Azathioprine; Bleomycin; Busulfan; Chlor | 1974 |
54 trials available for fluorouracil and Injuries, Radiation
| Article | Year |
|---|---|
Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cohort Stu | 2020 |
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; | 2020 |
Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2013 |
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Feasibility Studies; Female; Fluoroura | 2014 |
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2014 |
Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fraction | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
[Neoadjuvant short-term radiotherapy followed by FOLFOX chemotherapy : No standard treatment for rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Guide | 2016 |
[Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherap | 2017 |
Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2009 |
Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
[Extended preoperative course of radiotherapy as component of combined and complex treatment of locally-advanced ampular rectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluoro | 2010 |
Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Ther | 2011 |
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E | 2012 |
Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2012 |
Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Dose Fract | 2012 |
Alternating chemoradiotherapy in patients with nasopharyngeal cancer: prognostic factors and proposal for individualization of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2013 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera | 2013 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
Selenium in the treatment of radiation-associated secondary lymphedema.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 2003 |
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2003 |
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combi | 2004 |
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2004 |
[Preoperative concurrent radiation therapy and chemotherapy for operable bulky carcinomas of uterine cervix stages IB2, IIA, and IIB with proximal parametrial invasion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Cisplatin; Di | 2004 |
Phase II trial of hyperfractionated accelerated split-course radiochemotherapy with 5-FU and Cis-DDP in advanced head and neck cancer: results and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2004 |
Neoadjuvant accelerated chemotherapy followed by hyperfractionated radiation therapy in patients with operable, locally advanced head and neck carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2005 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2006 |
[Simultaneous radiochemotherapy and endoluminal HDR brachytherapy in esophageal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 2007 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2007 |
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2008 |
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Cyclopho | 2008 |
Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colo | 2008 |
Dose and volume effects on fibrosis after breast conservation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast Neoplasms; Cispla | 1994 |
Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophage | 1995 |
Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb | 1998 |
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 1999 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; C | 1999 |
Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Topics: Amifostine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Fluoro | 2000 |
Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 2001 |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined | 2001 |
Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fracti | 2001 |
Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2001 |
Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva.
Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Therapy, Combination; Fem | 1991 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A | 1985 |
[Side effects of adjuvant therapies of breast cancer: their significance for the patient].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1989 |
Combined 5-fluorouracil and radiation therapy following resection of locally advanced gastric carcinoma: a 5-years follow-up.
Topics: Adult; Aged; Clinical Trials as Topic; Combined Modality Therapy; Female; Fluorouracil; Follow-Up St | 1988 |
114 other studies available for fluorouracil and Injuries, Radiation
| Article | Year |
|---|---|
Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2020 |
Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel | 2021 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
The Prognostic Nutrition Index Predicts the Development of Hematological Toxicities in and the Prognosis of Esophageal Cancer Patients Treated with Cisplatin Plus 5-Fluorouracil Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2018 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; De | 2018 |
Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Edema; Cisplatin; Docetaxel; Female; Flu | 2018 |
Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2019 |
Effect of 5-fluorouracil on cellular response to proton beam in esophageal cancer cell lines according to the position of spread-out Bragg peak.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Survival; Dose-Response Relationship | 2019 |
Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma.
Topics: Analysis of Variance; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Fluorouracil; Humans; Leu | 2019 |
The heart's exposure to radiation increases the risk of cardiac toxicity after chemoradiotherapy for superficial esophageal cancer: a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Cardiotoxicity; Chemoradi | 2019 |
Gastric mucosal injury and hemorrhage after definitive chemoradiotherapy for locally advanced esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2019 |
Hypovolemic shock after pelvic radiotherapy. A rare combination leading to a devastating complication.
Topics: Aged; Anaphylaxis; Anus Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Colon, Si | 2019 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo | 2013 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brac | 2013 |
Intensity-modulated Radiation Therapy for Anal Cancer: Results From a Multi-Institutional Retrospective Cohort Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Cape | 2016 |
Loss of β-catenin triggers oxidative stress and impairs hematopoietic regeneration.
Topics: Animals; Antineoplastic Agents; beta Catenin; Bone Marrow; DNA Breaks, Double-Stranded; Fluorouracil | 2014 |
Late complications after proctectomy in rectal cancer patients who underwent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Agents; Case-C | 2014 |
IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycyt | 2014 |
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality The | 2014 |
Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2015 |
[Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell | 2015 |
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera | 2017 |
Images in clinical medicine. Radiation recall and woody fibrosis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Fluorouracil; Humans; Lumbar Verteb | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptotheci | 2017 |
Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell | 2015 |
Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Exocrine Pancreatic | 2016 |
[Clinical analysis of multimodal treatment for orbital organ preservation in T4b squamous cell carcinoma of nasal cavity and paranasal sinuses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2016 |
Lumbar-sacral bone marrow dose modeling for acute hematological toxicity in anal cancer patients treated with concurrent chemo-radiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow; Chemoradio | 2016 |
Fertility preservation for young women with rectal cancer--a combined approach from one referral center.
Topics: Adult; Antimetabolites, Antineoplastic; Cryopreservation; Female; Fluorouracil; Humans; Infertility, | 2009 |
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2009 |
Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chemotherapy, | 2009 |
High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
Topics: Adenocarcinoma; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Female; F | 2009 |
[Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dose-Response Relationship, Radiation; Fluorouracil; Huma | 2010 |
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deox | 2010 |
Radiochemotherapy including cisplatin alone versus cisplatin + 5-fluorouracil for locally advanced unresectable stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2009 |
High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Renal atrophy secondary to chemoradiotherapy of abdominal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; At | 2010 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Validation of the Total Dysphagia Risk Score (TDRS) as a predictive measure for acute swallowing dysfunction induced by chemoradiotherapy for head and neck cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-Squa | 2010 |
Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2011 |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer | 2011 |
[Early-onset radiation complications and tissue damage in the treatment of head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvant; | 2010 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 2011 |
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma | 2012 |
Quality of life outcomes in patients with anal cancer after combined radiochemotherapy.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anus Neoplasms; Chemotherapy, Adjuvant; | 2011 |
Primary lung cancer surgery after curative chemoradiotherapy for esophageal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2011 |
[Analysis of the factors related to esophageal injuries in radiotherapy of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Th | 2011 |
[Neoadjuvant radiochemotherapy for rectal cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Hu | 2011 |
Anastomotic complications after Ivor Lewis esophagectomy in patients treated with neoadjuvant chemoradiation are related to radiation dose to the gastric fundus.
Topics: Adult; Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherap | 2012 |
Radiotherapy-induced pemphigus vulgaris with autoantibodies targeting a 110 kDa epidermal antigen.
Topics: Acantholysis; Adrenal Cortex Hormones; Antigens; Antineoplastic Agents; Autoantibodies; Carcinoma; C | 2011 |
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac | 2012 |
Comparing cystatin C changes as a measure of renal function before and after radiotherapy in patients with stomach cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Urea Nitrogen; Capecitabine; Chemoradiother | 2012 |
Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell | 2012 |
Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of rad
Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fluorouracil; Hu | 2012 |
Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Intestin | 2013 |
[Hypersensitivity to radiation therapy in a patient with tuberous sclerosis: biological considerations about a clinical case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Ten-year results of chemoradiation for anal cancer: focus on late morbidity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Comb | 1996 |
Estimating risks of radiotherapy complications as part of informed consent: the high degree of variability between radiation oncologists may be related to experience.
Topics: Antimetabolites, Antineoplastic; Australia; Dose-Response Relationship, Radiation; Fluorouracil; Hea | 2002 |
Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemother | 2003 |
The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Thera | 2003 |
Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis.
Topics: Animals; Bromodeoxyuridine; Cheek; Coloring Agents; Cricetinae; Dose-Response Relationship, Drug; Fi | 2003 |
[RESEARCH ON CERTAIN DIGESTIVE DYSKINESIAS AND FUNCTIONAL DISORDERS].
Topics: Antiemetics; Apomorphine; Cobalt Isotopes; Cyclophosphamide; Digitalis Glycosides; Dyskinesias; Dysp | 1964 |
[Radiation-induced mucositis and neutrophil granulocytes in oral mucosa].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2003 |
Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
Topics: Animals; Cisplatin; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Fibroblast Growth F | 2005 |
Early occurrence of chylothorax related to thoracic irradiation and concomitant chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chylothorax; Cispl | 2005 |
Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; | 2005 |
Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 2006 |
Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2005 |
Quantification and reduction of cardiac dose in radical radiotherapy for oesophageal cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modalit | 2005 |
Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2006 |
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Female; Fluoroura | 2006 |
Acute proctocolitis with commencement of neoadjuvant chemoradiation for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; | 2006 |
Regression of radiation-induced macular edema after systemic bevacizumab.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab | 2007 |
Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-R | 2007 |
Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; | 1982 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
[Combination chemotherapy and radiotherapy. Differential effect, on the intestinal syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; Intestinal Dise | 1982 |
[Combination chemotherapy and radiotherapy. Differential effect, on the medullary syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Brain Diseases; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; | 1982 |
Carcinoma of the hand: a 20-year experience.
Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Female; Fluorouracil; Fol | 1984 |
[Retinoic acid and 5-FU mixture in the topical treatment of several skin diseases (author's transl)].
Topics: Drug Combinations; Fluorouracil; Humans; Keratosis; Ointments; Radiation Injuries; Skin Diseases; Sy | 1980 |
Protection of the gastrointestinal mucosa by elemental diets.
Topics: Animals; Fluorouracil; Food, Formulated; Humans; Hypotension; Intestinal Mucosa; Radiation Injuries; | 1980 |
[Therapy of anal cancer].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therap | 1994 |
Combined chemotherapy and radiation for bulky stages I-II cervical cancer: comparison of concurrent and sequential regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, A | 1993 |
High complete response rate of concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the uterine cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carcinoma, Sq | 1996 |
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 1997 |
Mature results of a pilot study of pelvic radiotherapy with concurrent continuous infusion intra-arterial 5-FU for stage IIIB-IVA squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; F | 1999 |
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla | 2000 |
Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Chemotherapy, Adjuvant; Dose-Response Relationshi | 2000 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom | 2001 |
Advanced head and neck cancer: long-term results of chemo-radiotherapy, complications and induction of second malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cobalt Radioisotopes; Combined Moda | 2001 |
Radiochemotherapy for anal carcinoma - effectivity and late toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2002 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
Trimodal combination therapy for maxillary sinus carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combin | 2002 |
Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1979 |
Delayed complications in colo-rectal carcinoma treated by combination radiotherapy and 5-fluorouracil--Eastern Cooperative Oncology Group (E.C.O.G.) pilot study.
Topics: Aged; Colonic Diseases; Colonic Neoplasms; Connective Tissue; Constriction, Pathologic; Female; Fluo | 1979 |
Delayed complications following combination of radiation and chemotherapy.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Neoplasms; Radiation Injuries; Radiation Tolerance; Res | 1979 |
Management of non-resectable (stage III) breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Drug Therap | 1979 |
[The therapeutic results and early and late toxicities of the treatment of anal canal carcinoma by radiotherapy or chemoradiotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combine | 1991 |
Chemo-irradiation induced aortoesophageal fistula.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Aortic Diseases; Cisplatin; Combine | 1991 |
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1990 |
Combined modality therapy for locally advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1990 |
[The effect of local UHF hyperthermia and a fractionated radiation dosage on the incidence of perichondritis during the treatment of laryngeal cancer].
Topics: Adult; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; In | 1990 |
A study of the late effects of radiotherapy and operation on patients with maxillary cancer. A survey more than 10 years after initial treatment.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Maxillary Neoplasms; Postoperative Complications; R | 1988 |
[Clinical evaluation of FAR therapy (radiotherapy with 5FU and vitamin A) for laryngeal cancer. II. Rates of control and complications].
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Neoplasms; Neoplasm Re | 1985 |
[Palliative treatment in patients with lung cancer].
Topics: Breast Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Methenolone; Palliative Care; Radiation Inju | 1971 |
5-Hydroxyindole-secreting rectal carcinoid tumour.
Topics: Adult; Carcinoid Tumor; Duodenal Ulcer; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Live | 1972 |
[The functional state of the liver during conservative treatment of oncologic patients].
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Esophageal Neoplasms; Fluorouracil; H | 1972 |